American Cancer Society Reports Latest Global Cancer Statistics; Cancer Cases Approach 21 Million Worldwide, With Burden Projected to Surge 67% by 2050
cancer - New data reveal stark geographic inequities and call for urgent global action on prevention, early detection, and equitable treatment access
AI Summary: The American Cancer Society published updated global cancer statistics showing cases near 21 million and projecting a steep rise by midcentury, highlighting shifting incidence patterns and growing health system strain. The report calls for intensified prevention, screening and investment in equitable cancer control to blunt the projected surge.
- GLOBOCAN and ACS: New global cancer estimates and projections (6)
- Regional responses: conferences, national programs, and research (4)
- Survival gaps: breast, GI, GU cancers and immunotherapy access (5)
- WHO 2026 Global Cancer Report: Urgent calls for action (5)
- All Other Stories
GLOBOCAN and ACS: New global cancer estimates and projections
Regional responses: conferences, national programs, and research
Survival gaps: breast, GI, GU cancers and immunotherapy access
WHO 2026 Global Cancer Report: Urgent calls for action
All Other Stories
For the First Time, a Cell Built From Scratch Grows and Divides
Yasemin Saplakoglu / quantamagazine - Scientists built a synthetic cell that combines more lifelike properties than ever before — proof of concept that it’s possible to bring nonliving materials to life, or something close to it, in the lab. The post For the First Time, a Cell Built From Scra…
AI Summary: Scientists have for the first time built a synthetic cell from scratch that completes a full life cycle — growing and dividing in the lab. The milestone demonstrates control over core cellular processes, opening doors for bespoke biomanufacturing and disease modelling, while reviving familiar ethical and biosafety questions. Yes, it’s breathtaking — and yes, we should probably be cautious.
First use of precision editing to study human embryo development reveals role of master gene
medicalxpress - Research led by the University of Cambridge Loke Center for Trophoblast Research has shown that a genome-editing technique can be used to alter a single gene in human embryonic cells, enabling the study of very early human development in unparalleled deta…
AI Summary: Scientists used precision genome editing in human embryos to identify a 'master' developmental gene that triggers early human development stages. The finding clarifies key molecular steps, offering insights into congenital disorders and embryology, but also reignites ethical debate over experimental editing — cue the lab‑coat philosophers.
AACR Report on Cancer Disparities and Health Equity
oncodaily - American Association for Cancer Research (AACR) shared a post on LinkedIn: “The AACR Cancer Disparities Progress Report 2026 is now available. The report outlines the myriad factors that drive and […]
AI Summary: The American Association for Cancer Research released a progress report detailing persistent gaps in cancer outcomes across race, ethnicity, socioeconomic status and geography. It documents uneven access to screening, trials and treatments, calls for targeted funding, workforce diversity and policy fixes, and urges measurable equity goals—because apparently pointing out the problem is step one.
- AACR report release and leadership outreach (4)
- Policy push: briefings, funding calls, and trial equity (4)
AACR report release and leadership outreach
Policy push: briefings, funding calls, and trial equity
Congressional Budget Office calls for more research on No Surprises Act unintended impacts
fiercehealthcare - The nonpartisan office is seeking more information on the law’s impact on healthcare prices, network participation, ownership structures and more.
AI Summary: The Congressional Budget Office has called for additional research into the No Surprises Act, urging deeper study of the law’s unintended consequences on pricing, provider networks and patient costs. Federal agencies and stakeholders are being pressed to produce better evidence so policymakers can evaluate whether the law’s goals align with real-world effects.
Florian Lordick Elected ESMO President 2029–2030
oncodaily - Professor Florian Lordick has been elected President of the European Society for Medical Oncology for the 2029–2030 term, marking a new leadership chapter for one of the world’s leading oncology […]
AI Summary: Florian Lordick will serve as ESMO president for 2029–2030, pledging to prioritise precision oncology, workforce development and stronger European collaboration. Colleagues praise his vision for translating research into practice and amplifying policy advocacy; expectations include initiatives to close care gaps and bolster international partnerships — because someone has to herd this many oncologists.
WellSpan Health, Philips launch 7-year AI, imaging partnership
Naomi Diaz / beckershospitalreview - York, Pa.-based WellSpan Health and Royal Philips have entered a seven-year strategic alliance covering advanced imaging technology, AI-enabled care and a joint research and co-development agreement across WellSpan’s 12 hospitals, diagnostic imaging cente…
AI Summary: WellSpan Health and Philips announced a seven-year collaboration to co-develop and deploy AI-enabled imaging solutions across the health system. The agreement aims to accelerate diagnostic imaging innovation, integrate AI into clinical workflows and support research — effectively a bet that smarter machines can shave time off scans and maybe improve patient outcomes.
In a First, Scientists Precisely Edit Human Embryo Genes
Carl Zimmer / nytimes - Researchers relied on a newer gene-editing technique that may make it possibl to engineer embryos, a prospect that has long alarmed bioethicists.
AI Summary: Researchers report the first precise edits to human embryo genes, demonstrating a technical milestone that immediately reopened the ethical and safety conversation about germline modification. Scientists urge caution, tighter oversight and more study before any clinical application while bioethicists debate whether we’ve crossed a line that’s been long teased in science fiction.
Pfizer’s $10.5B Deal With One of China’s Top Cancer Biotechs Is Another Sign the Game is Changing
Frank Vinluan / medcitynews - Pfizer unveiled a multi-drug R&D collaboration with Innovent Biologics, making it the latest big pharma company to reach a deal that taps into Chinese labs to source biotech innovation. This alliance will focus on developing next-generation drugs in the c…
AI Summary: Pfizer struck a $10.5 billion deal to acquire a leading Chinese oncology biotech, a transaction industry watchers say underlines China’s accelerating drug‑development muscle. Analysts flagged broader implications for global R&D competition, partnerships and where future oncology innovation — and manufacturing heft — might live.
How state laws can stymie research into your ancestors' psychiatric records
abcnews - Frustrated family members and others have been pushing for law changes in New York and other states that would allow the release of mental health records of long-dead ancestors
AI Summary: Legal researchers warn that a patchwork of state statutes and privacy rules is blocking access to historical psychiatric records needed for family‑history and population‑level studies. The restrictions complicate efforts to understand intergenerational mental‑health patterns and hamper reproducible research, leaving scientists to navigate inconsistent consent, archival access, and litigation risks.
Biogen, Denali to drop drug in non-genetic Parkinson’s after mid-stage study flop
Ayisha Sharma / endpoints - Biogen and Denali Therapeutics’ LRRK2 inhibitor has flunked a Phase 2b trial in early Parkinson’s disease, leading the companies to drop the program in certain patients. The small-molecule drug, known as BIIB122, missed the study’s ...
AI Summary: After disappointing mid‑stage results, developers have stopped advancement of a candidate Parkinson’s therapy for non‑genetic forms of the disease. The setback underscores the challenges of translating promising mechanisms into clinical benefit and will force sponsors to reassess pipelines and patient selection strategies.
Women’s experiences are forgotten in research on childbirth and breastfeeding
Thomas Saïas, Professeur de psychologie, Université du Québec à Montréal (UQAM) / theconversation - Two studies in the field of perinatal care show how, in the areas of breastfeeding and obstetrics, science prioritizes risk and the baby at the expense of mothers’ well-being.
AI Summary: New analyses show that research into childbirth and breastfeeding repeatedly sidelines women's firsthand experiences, prioritizing clinical metrics over lived realities. Experts warn this gap limits understanding of postpartum challenges, skews policy and perpetuates poorer care. Calls are growing for qualitative measures, patient-centered outcomes and inclusive study designs that actually listen to mothers.
- Clinical and policy focus on fetus over mothers' care (3)
- Mothers’ experiences ignored in childbirth and breastfeeding research (4)
- Women’s pain and reproductive conditions dismissed by medicine (4)
- All Other Stories
Clinical and policy focus on fetus over mothers' care
Mothers’ experiences ignored in childbirth and breastfeeding research
Women’s pain and reproductive conditions dismissed by medicine
All Other Stories
The peptide problem: Hype is outrunning the evidence
medicalxpress - Health Canada recently warned Canadians not to buy or inject unauthorized peptide drugs sold online, naming products that include BPC-157, CJC-1295, ipamorelin, TB-500 and retatrutide.
AI Summary: The booming market for peptide therapies and supplements is racing past the science. Researchers report limited clinical evidence, unclear long-term safety, and weak regulatory oversight, while consumer demand and marketing hype surge. Clinicians urge caution: biological plausibility isn’t the same as proven benefit, and enthusiasm should not substitute for rigorous trials.
Chiesi signs $1.9B deal to acquire KalVista and its approved drug
Kyle LaHucik / endpoints - Chiesi is buying commercial biotech KalVista Pharmaceuticals for about $1.9 billion in an extension of the industry's vigorous spring shopping spree. The Italian pharma will pay $27 per share {$KALV} in cash to buy the ...
AI Summary: Chiesi Group agreed to buy KalVista for $1.9 billion to secure an approved therapy and expand its rare-disease footprint. The deal transfers marketed assets and R&D capacity, positioning Chiesi to scale rare-disease revenues and invest in next-wave therapeutics — essentially a big check for a bigger strategic play.
Avalyn Pharma Takes a Breath to Raise $300M in IPO Cash for Lung Drug Trials
Frank Vinluan / medcitynews - Avalayn Pharma found strong investor interest in its inhalable drugs in development for two types of pulmonary fibrosis, enabling the company to upsize its IPO. Data from two mid-stage studies are expected in 2027. The post Avalyn Pharma Takes a Breath to…
AI Summary: Avalyn Pharma has substantially increased its IPO, targeting roughly $300 million to bankroll late-stage trials of its respiratory drug candidate. The move reflects strong investor enthusiasm for lung‑disease therapeutics and gives the company a bigger war chest to advance programs previously dependent on venture capital and partnerships.
FDA Announced Two Major Milestones in Implementing Real-Time Clinical Trials
oncodaily - U.S. Food and Drug Administration (FDA) shared a post on LinkedIn: “Today, the FDA announced two major milestones in implementing real-time clinical trials: Successful Proofs-of-Concept: FDA unveiled proof-of-concept trials with […]
AI Summary: The FDA announced major steps to implement real‑time clinical trial review through a new research collaboration, aiming to accelerate data flow and regulatory oversight. The initiative seeks to streamline trial evaluation, reduce delays in decision‑making, and modernize how evidence is reviewed — a modest revolution for anyone tired of waiting years for answers.
- AI, data and digital tools modernizing clinical trials (3)
- Equity, ethics and patient access in clinical trials (4)
- FDA real-time trial launches with academic and industry partners (4)
- All Other Stories
AI, data and digital tools modernizing clinical trials
Equity, ethics and patient access in clinical trials
FDA real-time trial launches with academic and industry partners
All Other Stories
11 cancers on the rise in young people - scientists find first clue why it's happening
bbc - Researchers stress that simple lifestyle changes can still significantly reduce the risk of cancer.
AI Summary: New studies report rising incidence of several cancers among younger adults, with England data showing increases in bowel and ovarian cancers and researchers claiming early clues to underlying drivers. Scientists are calling for urgent investigation into environmental, lifestyle, and diagnostic factors, enhanced surveillance and prevention measures — because apparently youth is no longer a guarantee.
- New lab discoveries point to targeted, immune-based cancer therapies (4)
- Other health stories: infections, liver care, social impacts on youth (5)
- Prevention and screening gaps risk late diagnoses, experts warn (4)
- Younger adults facing rising cancers — investigators hunt environmental culprits (7)
- All Other Stories
New lab discoveries point to targeted, immune-based cancer therapies
Other health stories: infections, liver care, social impacts on youth
Prevention and screening gaps risk late diagnoses, experts warn
Younger adults facing rising cancers — investigators hunt environmental culprits
All Other Stories
First-Ever Smell Map Is a Breakthrough in Sensory Research, a Step to Help Us Tackle Loss of Smell
discovermagazine - Discover how smell receptors in our noses aren’t randomly arranged but are highly organized, offering new paths toward treating sensory impairment.
AI Summary: Scientists have produced the first high‑resolution olfactory map, charting how scent receptors and neural circuits are organized in the nose. The atlas exposes unexpected patterns in odor encoding, helps explain smell loss, and points to new diagnostic and therapeutic pathways — including potential early markers of Alzheimer’s‑related olfactory damage.
- Hidden nose atlas rewrites smell organization, flags Alzheimer links (4)
- New brain markers and tests for early Alzheimer detection (4)
- All Other Stories
Hidden nose atlas rewrites smell organization, flags Alzheimer links
New brain markers and tests for early Alzheimer detection
All Other Stories
Erectile disorder: How science is moving beyond Viagra
medicalxpress - Erectile disorder (ED) refers to a persistent difficulty achieving or maintaining an erection sufficient for satisfying sexual activity. It affects millions of men worldwide, including up to 1 in 4 in the United States. Beyond physical functioning, erecti…
AI Summary: Researchers are advancing alternatives to sildenafil-era approaches for erectile disorder, exploring new biological targets and therapies that aim to restore function rather than just patch symptoms. The coverage explains emerging mechanisms, investigational treatments and the shifting clinical landscape—because sometimes a Band-Aid on performance isn’t the long-term plan.
Eugene Braunwald, Whose Research Reshaped Cardiology, Dies at 96
Jonathan Kandell / nytimes - His work changed how doctors understood heart attacks, heart failure and coronary artery disease, and helped lead to therapies that saved millions of lives.
AI Summary: Eugene Braunwald, a towering figure whose research reshaped modern cardiology, has died at 96. Colleagues remember his seminal contributions to cardiac physiology, therapeutics, and clinical practice that set the stage for decades of advances. His passing marks the end of an era for a field he helped steer.